Please login to the form below

Not currently logged in
Email:
Password:

Haemostatix receives Wellcome Trust Award

Biopharma Haemostatix is to receive a £409,000 Translation Award from the Wellcome Trust to support development of its haemostat technology

Biopharmaceutical company, Haemostatix, is to receive a £409,000 Translation Award from the Wellcome Trust to support development of its innovative haemostat technology, used by surgeons to manage problematic bleeding and to reduce time in the operating theatre during surgery. The products are applied in the form of sprays, gels or pads, and typically contain the enzyme thrombin, which promotes blood clotting, as the active ingredient.

Haemostatix has developed a new class of active ingredient based on a peptide that binds to another blood clotting protein, fibrinogen, instantly forming a clot.

Dr Ben Nichols, CEO of Haemostatix, commented: "There is a real need for rapid acting, ready-to-use haemostats that are safe and cost-effective, and we believe our technology can deliver these benefits to surgeons and their patients. We have received a lot of interest from pharmaceutical companies, and this Award and the investment, will enable us to generate more data to support the commercialisation process."

Dr Richard Seabrook, head of business development at the Wellcome Trust, said: "Bleeding is a major cause of mortality during trauma and control of bleeding during surgery is essential to the outcome of procedures. If successful, a new haemostat that bypasses the need for thrombin has the potential to make a huge impact on healthcare and the Wellcome Trust is pleased to support this project."

The funding coincides with an additional £459,000 investment from Spark Ventures, Catapult Venture Managers, NESTA, the Lachesis Fund and Leicester University, as well as new investor, Mobius Life Sciences Fund.

Haemostatix is based at BioCity Nottingham, Europe's largest bioscience business incubator and was originally a spin-out from Leicester University. Dr Glenn Crocker, CEO of BioCity added: "We have provided Haemostatix with a supportive business development environment for several years and recognise the enormous progress the company has made with its new product. Mobius Life Sciences Fund is designed to contribute to this kind of investment opportunity alongside major investors and we look forward to Haemostatix' further success."

8th November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics